3D printing continues to be one of the most attractive industries for individual investors right now. And with the European debt crisis and slowing growth in China, we may – if given the room – be able to innovate our way to an American Renaissance.
Since the technology is still in its infancy, it’s not too late to grab a slice of the pie.
Today, we’re going to cover one company that’s found an interesting niche in this market.
Opposite of 3D Systems, the current leader in the consumer market, on the publicly traded 3-D printing spectrum is ExOne (NASDAQ: XONE), the relatively new kid on the block.
Since becoming a public company on Feb. 8, ExOne has been the preferred stock out of the 3-D printing “pure plays”, doubling since its IPO.
The company is currently operating in Asia, Europe and North and South America.
ExOne operates almost entirely in the industrial, large-scale market, catering to large manufacturers in industries like automotive production. Notable products include the S-Max, S-Print, and M-Print.
M-Lab, however, serves another interesting market segment for ExOne: the researchers and educational customers space. As one of the smallest printers available by ExOne, M-Lab is particularly designed to be used in labs.
While other pure plays like 3D Systems or Stratasys sell printers in volume, ExOne sells a small number of large-scale printers. These printers sell for a hefty cost, measured in the millions. In 2012, for example, they sold only 13 machines, but generated roughly $16 million in revenue.
While customers have to pay a pretty penny for ExOne’s 3-D printers, and sales are expected to increase for 2013, that’s not where the company expects to garner their main source of revenue.
Its main source, it turns out, derives from strategically located public service centers (PSCs) in industrial, high-manufacturing areas. With only five stationed PSCs, the arrangement accounted for 45% of ExOne’s 2012 sales. The company plans to expand to 15 PSCs by the year 2015, which will help ExOne attain a goal of $100 million in revenue, and gross margins exceeding 50%, set by CEO Kent Rockwell.
Although ExOne has yet to post positive earnings, it looks to be on the path to profits. If other public 3-D printing manufacturers serve as a guide, it may improve its bottom line substantially in this rapidly growing market.
So what’s my take on it?
Although 200% year-over-year revenue growth makes it a tempting prospect, the company is starting from a very small base. The company reported only $33.9 million in revenue over the past 12 months and currently trades at 20.5 times sales. It could, however, catch up to its lofty valuation if it does what it’s competition is doing: acquire prospects like there’s no tomorrow.
Here’s one speculation I’d like to share. There’s a gold rush on to stake a claim in the rapidly expanding 3-D printing market. 3-D printing behemoths such as 3D Systems and Stratasys have been on an acquisition binge. Stratasys, for example, recently acquired consumer 3-D printing specialist MakerBot. ExOne is on track to grow revenues from companies seeking to take advantage of its metal printing technology. It’s possible that ExOne, with a market cap of under $1 billion, could become an acquisition target.
It will be interesting to see how ExOne fares as it penetrates the high end of the market, making it a good for any watch list.
Josh Grasmickfor, Tomorrow in Review
These new materials can shift shapes in response to outside forces, such as contact with water, air, gravity, magnets and/or temperature change. “The idea behind 4-D printing,” says director of MIT’s Self-Assembly Lab Skylar Tibbits, “is that you take multimaterial 3-D printing… and you add a new capability, which is transformation.”
Josh Grasmick is managing editor of Tomorrow in Review and associate editor of Technology Profits Confidential and Breakthrough Technology Alert. After graduating from Washington College with a degree in English, the self-described autodidact was interviewed by Time magazine for his novel entrepreneurship and worldwide eco-adventures. His experience with those in the fields of science, medicine and technology puts readers ahead of the curve and on top of the market.
Even if tech giants like Facebook and Apple have a down day now and then, that doesn't mean they aren't still sound companies with upside potential. Of course, some people aren't convinced... which is why the word "bubble" has now reentered the conversation. Dave Gonigam has the full story...
Gold has had a rough go of it since the 2008 financial crisis. But according to Matt Insley, there is now a very clear price floor for the yellow metal. And what's more interesting, he comes to this conclusion by way of a glass of chocolate milk and Janet Yellen's actions from here throne at the Eccles Building. Read on...
The recent spate of new tech-based IPOs has a few prominent investors (Ahem... David Einhorn) touting the return of the '90s tech bubble. But there are some very good reasons why this market is nothing like the '90s, and why investors should be wary of any advice to the contrary. Paul Mampilly explains...
Generic drugs are supposed to lower healthcare costs and provide you with another medical alternative. That's what it says on paper. But there's a real danger that goes along with these drugs. A danger even your doctor might not be aware of... Dr. David Eifrig has the full story. Read on...
The solar panel turns 60 on Friday, but this birthday celebration will be unlike any other the industry has seen so far. In the past, solar energy's high price tag meant its wide-spread usage was nothing more than a pipe dream. But now, after six decades, solar power may finally be cheaper than oil and Asian liquefied-natural-gas. Greg Guenthner has more...